hydroxyurea has been researched along with Hematologic Diseases in 18 studies
Hematologic Diseases: Disorders of the blood and blood forming tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Five patients treated with hydroxyurea for various haematological malignancies developed multiple painful oral ulcers." | 7.69 | Painful oral ulcers with hydroxyurea therapy. ( Ainoon, O; Cheong, SK; Hamidah, NH; Norhaya, MR, 1997) |
| "In an attempt to improve the primary treatment of malignant gliomas we used a concomitant 6-week course of chemoradiotherapy with 5 fluorouracil (5 FU) and hydroxyurea (HU) in 24 adults with anaplastic astrocytoma (AA) (7 cases) or glioblastomas (GLB) (17 cases)." | 5.07 | Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas. ( Armand, JP; Cioloca, C; Constans, JP; Cvitkovic, FB; Haie-Meder, C; Maugis, N; Papadimitrakopoulou, V, 1993) |
| "Five patients treated with hydroxyurea for various haematological malignancies developed multiple painful oral ulcers." | 3.69 | Painful oral ulcers with hydroxyurea therapy. ( Ainoon, O; Cheong, SK; Hamidah, NH; Norhaya, MR, 1997) |
| "Hydroxyurea was temporarily discontinued for predefined toxicity." | 2.70 | A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. ( Lane, PA; Rogers, ZR; Scott, JP; Wang, WC; Ware, RE; Wynn, LW, 2001) |
| "Patients with advanced colorectal cancer and no prior chemotherapy were randomized to six treatment regimens: A) fluorouracil (FU) alone; B) FU + hydroxyurea (HU); C) semustine (SE) + dacarbazine (DA); D) FU + HU alternating with SE + DA; E) SE + razoxane (RA); F) mitomycin (MI) + DA." | 2.65 | Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278). ( Engstrom, PF; Klaassen, DJ; MacIntyre, JM; Mittelman, A, 1984) |
| "Prepubertal patients with childhood cancer or hematological disorders were more likely to have significantly reduced spermatogonial quantity compared to healthy controls (48." | 1.91 | Childhood cancer and hematological disorders negatively affect spermatogonial quantity at diagnosis: a retrospective study of a male fertility preservation cohort. ( Feijen, EAM; Goossens, E; Jahnukainen, K; Kremer, LMC; Masliukaite, I; Meissner, A; Ntemou, E; Repping, S; Soufan, AT; van de Wetering, M; van Pelt, AMM, 2023) |
| "The pleural effusion was transudative, although there was no history of cardiac failure or hypoalbuminemia, and treatment with diuretics failed." | 1.62 | Transudative Pleural Effusion Associated with Extramedullary Hematopoiesis. ( Amaki, J; Aoki, T; Asano, K; Enokida, K; Hayama, N; Oguma, T; Okada, N; Takeuchi, T; Takihara, T; Tomomatsu, K, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (27.78) | 18.7374 |
| 1990's | 4 (22.22) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Masliukaite, I | 1 |
| Ntemou, E | 1 |
| Feijen, EAM | 1 |
| van de Wetering, M | 1 |
| Meissner, A | 1 |
| Soufan, AT | 1 |
| Repping, S | 1 |
| Kremer, LMC | 1 |
| Jahnukainen, K | 1 |
| Goossens, E | 1 |
| van Pelt, AMM | 1 |
| Enokida, K | 1 |
| Tomomatsu, K | 1 |
| Okada, N | 1 |
| Takeuchi, T | 1 |
| Takihara, T | 1 |
| Amaki, J | 1 |
| Hayama, N | 1 |
| Oguma, T | 1 |
| Aoki, T | 1 |
| Asano, K | 1 |
| Russo, G | 1 |
| De Franceschi, L | 1 |
| Colombatti, R | 1 |
| Rigano, P | 1 |
| Perrotta, S | 1 |
| Voi, V | 1 |
| Palazzi, G | 1 |
| Fidone, C | 1 |
| Quota, A | 1 |
| Graziadei, G | 1 |
| Pietrangelo, A | 1 |
| Pinto, V | 1 |
| Ruffo, GB | 1 |
| Sorrentino, F | 1 |
| Venturelli, D | 1 |
| Casale, M | 1 |
| Ferrara, F | 1 |
| Sainati, L | 1 |
| Cappellini, MD | 1 |
| Piga, A | 1 |
| Maggio, A | 1 |
| Forni, GL | 1 |
| Tsai, M | 1 |
| Kita, A | 1 |
| Leach, J | 1 |
| Rounsevell, R | 1 |
| Huang, JN | 1 |
| Moake, J | 1 |
| Ware, RE | 2 |
| Fletcher, DA | 1 |
| Lam, WA | 1 |
| Kühr, T | 1 |
| Burgstaller, S | 1 |
| Apfelbeck, U | 1 |
| Linkesch, W | 1 |
| Seewann, H | 1 |
| Fridrik, M | 1 |
| Michlmayr, G | 1 |
| Krieger, O | 1 |
| Lutz, D | 1 |
| Lin, W | 1 |
| Pont, J | 1 |
| Köck, L | 1 |
| Abbrederis, K | 1 |
| Baldinger, C | 1 |
| Buder, R | 1 |
| Geissler, D | 1 |
| Hausmaninger, H | 1 |
| Lang, A | 1 |
| Zabernigg, A | 1 |
| Duba, C | 1 |
| Hilbe, W | 1 |
| Eisterer, W | 1 |
| Fiegl, M | 1 |
| Greil, R | 1 |
| Gastl, G | 1 |
| Thaler, J | 1 |
| Louvet, C | 1 |
| Carrat, F | 1 |
| Mal, F | 1 |
| Mabro, M | 1 |
| Beerblock, K | 1 |
| Vaillant, JC | 1 |
| Cady, J | 1 |
| André, T | 1 |
| Gamelin, E | 1 |
| de Gramont, A | 1 |
| SAMUELS, ML | 1 |
| HOWE, CD | 1 |
| Hampton, T | 1 |
| Engstrom, PF | 1 |
| MacIntyre, JM | 1 |
| Mittelman, A | 1 |
| Klaassen, DJ | 1 |
| Kaneko, S | 1 |
| Motomura, S | 1 |
| Ibayashi, H | 1 |
| Cvitkovic, FB | 1 |
| Haie-Meder, C | 1 |
| Papadimitrakopoulou, V | 1 |
| Armand, JP | 1 |
| Cioloca, C | 1 |
| Maugis, N | 1 |
| Constans, JP | 1 |
| Norhaya, MR | 1 |
| Cheong, SK | 1 |
| Ainoon, O | 1 |
| Hamidah, NH | 1 |
| Ballas, SK | 1 |
| Navarra, P | 1 |
| Preziosi, P | 1 |
| Powars, DR | 1 |
| Wang, WC | 1 |
| Wynn, LW | 1 |
| Rogers, ZR | 1 |
| Scott, JP | 1 |
| Lane, PA | 1 |
| Froom, P | 1 |
| Quitt, M | 1 |
| Aghai, E | 1 |
| Richards, GJ | 1 |
| Chambers, RG | 1 |
3 reviews available for hydroxyurea and Hematologic Diseases
| Article | Year |
|---|---|
Current challenges in the management of patients with sickle cell disease - A report of the Italian experience.
Topics: Anemia, Sickle Cell; Disease Management; Hematologic Diseases; Hemoglobinopathies; Humans; Hydroxyur | 2019 |
Complications of sickle cell anemia in adults: guidelines for effective management.
Topics: Adult; Analgesics, Opioid; Anemia, Sickle Cell; Brain Diseases; Chest Pain; Child; Child, Preschool; | 1999 |
Hydroxyurea: new insights on an old drug.
Topics: Arthritis, Rheumatoid; Hematologic Diseases; Humans; Hydroxyurea; Neoplasms; Ribonucleotide Reductas | 1999 |
4 trials available for hydroxyurea and Hematologic Diseases
| Article | Year |
|---|---|
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gastrointestinal Di | 2003 |
Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1984 |
Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined | 1993 |
A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
Topics: Age Factors; Anemia, Sickle Cell; Antisickling Agents; Blood Cell Count; Child, Preschool; Feasibili | 2001 |
11 other studies available for hydroxyurea and Hematologic Diseases
| Article | Year |
|---|---|
Childhood cancer and hematological disorders negatively affect spermatogonial quantity at diagnosis: a retrospective study of a male fertility preservation cohort.
Topics: Adult; Child; Cryopreservation; Fertility Preservation; Hematologic Diseases; Humans; Hydroxyurea; M | 2023 |
Transudative Pleural Effusion Associated with Extramedullary Hematopoiesis.
Topics: Aged; Hematologic Diseases; Hematopoiesis, Extramedullary; Humans; Hydroxyurea; Male; Pleural Effusi | 2021 |
In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology.
Topics: Anemia, Sickle Cell; Eptifibatide; Hematologic Diseases; Hemolytic-Uremic Syndrome; Hemorheology; Hu | 2012 |
Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen).
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2003 |
RENAL ABNORMALITIES INDUCED BY HYDROXYUREA (NSC-32065).
Topics: Antineoplastic Agents; Blood; Hematologic Diseases; Hematuria; Hydroxyurea; Kidney Diseases; Kidney | 1964 |
Strides made in red blood cell disorders, but substantial barriers to care remain.
Topics: Anemia, Sickle Cell; Antisickling Agents; Benzoates; Brain Diseases; Chelation Therapy; Deferasirox; | 2008 |
Differentiation of human bone marrow-derived fibroblastoid colony forming cells (CFU-F) and their roles in haemopoiesis in vitro.
Topics: Adipose Tissue; Cell Count; Cell Differentiation; Cell Survival; Cells, Cultured; Dose-Response Rela | 1982 |
Painful oral ulcers with hydroxyurea therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Hematologi | 1997 |
Hydroxyurea in very young children with sickle cell anemia is not a cure-all.
Topics: Age Factors; Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Hematologic Diseases; Human | 2001 |
The mean leukocyte myeloperoxidase index in hematological patients.
Topics: Hematologic Diseases; Hospitalization; Humans; Hydroxyurea; Leukocytes; Lymphoma; Lymphoma, Non-Hodg | 1989 |
Hydroxyurea: a radiosensitizer in the treatment of neoplasms of the head and neck.
Topics: Adult; Age Factors; Aged; Female; Gastrointestinal Diseases; Head; Head and Neck Neoplasms; Hematolo | 1969 |